APA (7th ed.) Citation

Morschhauser, F., Ghosh, N., Lossos, I., Palomba, M., Mehta, A., Casasnovas, O., . . . Salles, G. (2019). EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematological oncology, 37, 113. https://doi.org/10.1002/hon.74_2629

Chicago Style (17th ed.) Citation

Morschhauser, F., et al. "EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL." Hematological Oncology 37 (2019): 113. https://doi.org/10.1002/hon.74_2629.

MLA (9th ed.) Citation

Morschhauser, F., et al. "EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL." Hematological Oncology, vol. 37, 2019, p. 113, https://doi.org/10.1002/hon.74_2629.